Healthcare News and Research

Latest Healthcare News and Research

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Study points to need for improving pediatric benefits under the Affordable Care Act

An article published in the Health Affairs December issue is the first ever comprehensive analysis to investigate the Affordable Care Act's (ACA) Essential Health Benefit (EHB) as it relates to children. The study found that the EHB has resulted in a state-by-state patchwork of coverage for children and adolescents that has significant exclusions, particularly for children with developmental disabilities and other special health care needs.

9 Dec 2014

Better planning needed to improve mother-infant outcomes in hospitals, say CHOP researchers

What does it mean for expectant mothers and hospitals when there are large-scale closures of maternity units? A new study led by researchers at The Children's Hospital of Philadelphia provides an inside view from hospital staff members in Philadelphia, where 13 out of 19 obstetric units closed in a 15-year period.

9 Dec 2014

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells.

9 Dec 2014

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Aiming to empower planners and policy-makers to achieve better health for billions of people living in fast-growing urban areas, world health, environmental, behavioural and social science experts today launched a major new interdisciplinary scientific collaboration.

9 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Nationwide Children's Hospital receives ANCC Magnet Recognition for third time

The American Nurses Credentialing Center's Magnet Recognition Program for excellence in nursing services has granted Nationwide Children's Hospital ANCC Magnet Recognition for a third time. This prestigious recognition is the ultimate benchmark in nursing excellence and is awarded to only about seven percent of the nation's more than 6,000 hospitals across the country.

8 Dec 2014

UTHealth receives $7.3 million grant to research on health information technology

The University of Texas Health Science Center at Houston School of Biomedical Informatics has been awarded grants totaling $7.3 million to enhance health care and biomedical discovery through the use of health information technology.

8 Dec 2014

Findings open new avenues for research to predict risk of therapy-related AML

For a small percentage of cancer patients, treatment aimed at curing the disease leads to a form of leukemia with a poor prognosis. Conventional thinking goes that chemotherapy and radiation therapy induce a barrage of damaging genetic mutations that kill cancer cells yet inadvertently spur the development of acute myeloid leukemia (AML), a blood cancer.

8 Dec 2014

Older Latinos living in safe, walkable neighborhoods less likely to develop severe depressive symptoms

Older Latinos living in the U.S. who perceive their neighborhoods as safer and more walkable are less likely to develop severe depressive symptoms, and the effect may be long term, a new study suggests.

8 Dec 2014

Verizon announces winners of 2014 Powerful Answers Award

The wait is over. Verizon is proud to announce the winners of Verizon's 2014 Powerful Answers Award, three in each of the following categories: education, health care, sustainability and transportation.

8 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Continuous glucose monitoring (CGM) mobile communications: an interview with Jorge Valdes

Type 1 diabetes is a complex condition to manage. It requires continuous, around the clock monitoring of blood glucose levels, which change repeatedly throughout the day and night.

7 Dec 2014

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment.

From Novo Nordisk 7 Dec 2014

New report examines how companies educate employees, prepare for new product launch

When a pharmaceutical company is gearing up for a new product launch, effective brand and communications leaders focus not only on external communications but also internal disease state communication and education directed at employees.

7 Dec 2014

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Healthcare News and Research

Latest Healthcare News and Research

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Study points to need for improving pediatric benefits under the Affordable Care Act

Better planning needed to improve mother-infant outcomes in hospitals, say CHOP researchers

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Nationwide Children's Hospital receives ANCC Magnet Recognition for third time

UTHealth receives $7.3 million grant to research on health information technology

Findings open new avenues for research to predict risk of therapy-related AML

Older Latinos living in safe, walkable neighborhoods less likely to develop severe depressive symptoms

Verizon announces winners of 2014 Powerful Answers Award

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Continuous glucose monitoring (CGM) mobile communications: an interview with Jorge Valdes

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

New report examines how companies educate employees, prepare for new product launch

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Healthcare News and Research

Latest Healthcare News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in